Literature DB >> 9930670

Misfolding of chloramphenicol acetyltransferase due to carboxy-terminal truncation can be corrected by second-site mutations.

J Van der Schueren1, J Robben, G Volckaert.   

Abstract

Folding of chloramphenicol acetyltransferase (CAT) in Escherichia coli is hampered by deletion of the carboxy-terminal tail including the last residue of the carboxy-terminal alpha-helix. Such truncated CAT polypeptides quantitatively aggregate into cytoplasmic inclusion bodies, which results in absence of a chloramphenicol-resistant phenotype for the producing host. In this paper, a genetic approach is presented to examine this aggregation process in more detail. Random mutagenesis of inactive CAT followed by direct phenotypic selection for revertants with restored chloramphenicol resistance was used to isolate second-site suppressors of inactive truncation mutants of CAT. Two random mutagenesis procedures, independently of each other, yielded a unique substitution of Phe for Leu at amino acid position 145. This second-site mutation does not drastically affect the proteins' stability under normal growth conditions of E. coli. Hence, the introduction of Phe at amino acid position 145 improves the ability of the protein to fold into a soluble, enzymatically active conformation. The conservative character of the Leu145Phe replacement indicates that limited changes at crucial positions can have important effects on protein folding in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9930670     DOI: 10.1093/protein/11.12.1211

Source DB:  PubMed          Journal:  Protein Eng        ISSN: 0269-2139


  3 in total

1.  Use of a cryptic splice donor site in the chloramphenicol acetyltransferase (CAT)-SV40 small-t antigen cassette generates alternative transcripts in transgenic rats.

Authors:  Z D Burke; T Wells; D A Carter; R Baler
Journal:  Transgenic Res       Date:  2000-02       Impact factor: 2.788

Review 2.  'Let the phage do the work': using the phage P22 coat protein structures as a framework to understand its folding and assembly mutants.

Authors:  Carolyn M Teschke; Kristin N Parent
Journal:  Virology       Date:  2010-03-16       Impact factor: 3.616

3.  A plasmid toolkit for cloning chimeric cDNAs encoding customized fusion proteins into any Gateway destination expression vector.

Authors:  Raquel Buj; Noa Iglesias; Anna M Planas; Tomàs Santalucía
Journal:  BMC Mol Biol       Date:  2013-08-20       Impact factor: 2.946

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.